These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 22333597)

  • 1. Aberrant activation of the mTOR pathway and anti-tumour effect of everolimus on oesophageal squamous cell carcinoma.
    Hirashima K; Baba Y; Watanabe M; Karashima RI; Sato N; Imamura Y; Nagai Y; Hayashi N; Iyama KI; Baba H
    Br J Cancer; 2012 Feb; 106(5):876-82. PubMed ID: 22333597
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The activity of mTOR inhibitor RAD001 (everolimus) in nasopharyngeal carcinoma and cisplatin-resistant cell lines.
    Ma BB; Lui VW; Hui EP; Lau CP; Ho K; Ng MH; Cheng SH; Tsao SW; Chan AT
    Invest New Drugs; 2010 Aug; 28(4):413-20. PubMed ID: 19471857
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-tumor effect of the mammalian target of rapamycin inhibitor everolimus in oral squamous cell carcinoma.
    Naruse T; Yanamoto S; Yamada S; Rokutanda S; Kawakita A; Kawasaki G; Umeda M
    Pathol Oncol Res; 2015 Jul; 21(3):765-73. PubMed ID: 25682238
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined targeting of mTOR and c-MET signaling pathways for effective management of epithelioid sarcoma.
    Imura Y; Yasui H; Outani H; Wakamatsu T; Hamada K; Nakai T; Yamada S; Myoui A; Araki N; Ueda T; Itoh K; Yoshikawa H; Naka N
    Mol Cancer; 2014 Aug; 13():185. PubMed ID: 25098767
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A dual mTORC1 and mTORC2 inhibitor shows antitumor activity in esophageal squamous cell carcinoma cells and sensitizes them to cisplatin.
    Huang Y; Xi Q; Chen Y; Wang J; Peng P; Xia S; Yu S
    Anticancer Drugs; 2013 Oct; 24(9):889-98. PubMed ID: 23838676
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phosphorylated p70S6K expression is an independent prognosticator for patients with esophageal squamous cell carcinoma.
    Li SH; Chen CH; Lu HI; Huang WT; Tien WY; Lan YC; Lee CC; Chen YH; Huang HY; Chang AY; Lin WC
    Surgery; 2015 Mar; 157(3):570-80. PubMed ID: 25726316
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved clearance during treatment of HPV-positive head and neck cancer through mTOR inhibition.
    Coppock JD; Wieking BG; Molinolo AA; Gutkind JS; Miskimins WK; Lee JH
    Neoplasia; 2013 Jun; 15(6):620-30. PubMed ID: 23730210
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FOXO3a reactivation mediates the synergistic cytotoxic effects of rapamycin and cisplatin in oral squamous cell carcinoma cells.
    Fang L; Wang H; Zhou L; Yu D
    Toxicol Appl Pharmacol; 2011 Feb; 251(1):8-15. PubMed ID: 21092744
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumor effect of the mTOR inhibitor everolimus in combination with trastuzumab on human breast cancer stem cells in vitro and in vivo.
    Zhu Y; Zhang X; Liu Y; Zhang S; Liu J; Ma Y; Zhang J
    Tumour Biol; 2012 Oct; 33(5):1349-62. PubMed ID: 22492237
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The mTOR pathway affects proliferation and chemosensitivity of urothelial carcinoma cells and is upregulated in a subset of human bladder cancers.
    Makhlin I; Zhang J; Long CJ; Devarajan K; Zhou Y; Klein-Szanto AJ; Huang M; Chernoff J; Boorjian SA
    BJU Int; 2011 Jul; 108(2 Pt 2):E84-90. PubMed ID: 21050361
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanistic target of rapamycin small interfering RNA and rapamycin synergistically inhibit tumour growth in a mouse xenograft model of human oesophageal carcinoma.
    Sun MM; Zhang MZ; Chen Y; Li SL; Zhang W; Ya GW; Chen KS
    J Int Med Res; 2012; 40(5):1636-43. PubMed ID: 23206445
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of cell growth and up-regulation of MAD2 in human oesophageal squamous cell carcinoma after treatment with the Src/Abl inhibitor dasatinib.
    Wang L; Guo B; Wang R; Jiang Y; Qin S; Liang S; Zhao Y; Guo W; Li K; Fan X
    Clin Sci (Lond); 2012 Jan; 122(1):13-24. PubMed ID: 21751967
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Schedule-dependent inhibition of T-cell lymphoma cells by cotreatment with the mTOR inhibitor everolimus and anticancer drugs.
    Huang JJ; Li ZM; Huang Y; Huang Y; Tian Y; He XX; Xiao J; Lin TY
    Invest New Drugs; 2012 Feb; 30(1):223-35. PubMed ID: 20960030
    [TBL] [Abstract][Full Text] [Related]  

  • 14. mTOR inhibitor RAD001 (everolimus) induces apoptotic, not autophagic cell death, in human nasopharyngeal carcinoma cells.
    Cai Y; Xia Q; Su Q; Luo R; Sun Y; Shi Y; Jiang W
    Int J Mol Med; 2013 Apr; 31(4):904-12. PubMed ID: 23426850
    [TBL] [Abstract][Full Text] [Related]  

  • 15. OP16, a novel ent-kaurene diterpenoid, potentiates the antitumor effect of rapamycin by inhibiting rapamycin-induced feedback activation of Akt signaling in esophageal squamous cell carcinoma.
    Peng KZ; Ke Y; Zhao Q; Tian F; Liu HM; Hou G; Lu Z
    Biochem Pharmacol; 2017 Sep; 140():16-27. PubMed ID: 28539264
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual inhibition of PI3K and mTOR mitigates compensatory AKT activation and improves tamoxifen response in breast cancer.
    Chen X; Zhao M; Hao M; Sun X; Wang J; Mao Y; Zu L; Liu J; Shen Y; Wang J; Shen K
    Mol Cancer Res; 2013 Oct; 11(10):1269-78. PubMed ID: 23814023
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of mTOR inhibitor everolimus (RAD001) on bladder cancer cells.
    Chiong E; Lee IL; Dadbin A; Sabichi AL; Harris L; Urbauer D; McConkey DJ; Dickstein RJ; Cheng T; Grossman HB
    Clin Cancer Res; 2011 May; 17(9):2863-73. PubMed ID: 21415218
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activity of the mTOR inhibitor RAD001, the dual mTOR and PI3-kinase inhibitor BEZ235 and the PI3-kinase inhibitor BKM120 in hepatocellular carcinoma.
    Kirstein MM; Boukouris AE; Pothiraju D; Buitrago-Molina LE; Marhenke S; Schütt J; Orlik J; Kühnel F; Hegermann J; Manns MP; Vogel A
    Liver Int; 2013 May; 33(5):780-93. PubMed ID: 23489999
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of rituximab and mammalian target of rapamycin inhibitor everolimus (RAD001) in diffuse large B-cell lymphoma.
    Xu ZZ; Wang WF; Fu WB; Wang AH; Liu ZY; Chen LY; Guo P; Li JM
    Leuk Lymphoma; 2014 May; 55(5):1151-7. PubMed ID: 23841505
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of vatalanib on tumor growth can be potentiated by mTOR blockade in vivo.
    Jaeger-Lansky A; Cejka D; Ying L; Preusser M; Hoeflmayer D; Fuereder T; Koehrer S; Wacheck V
    Cancer Biol Ther; 2010 Jun; 9(11):919-27. PubMed ID: 20404549
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.